Clinical data | |
---|---|
Trade names | Bumex, Burinex, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a684051 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intravenous, intramuscular |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Almost complete (~80%) |
Protein binding | 97% |
Metabolism | Liver |
Elimination half-life | ~0.8 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.044.534 |
Chemical and physical data | |
Formula | C17H20N2O5S |
Molar mass | 364.42 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Bumetanide, sold under the brand name Bumex among others, is a medication used to treat swelling and high blood pressure.[2] This includes swelling as a result of heart failure, liver failure, or kidney problems.[2] It may work for swelling when other medications have not.[2] For high blood pressure it is not a preferred treatment.[2] It is taken by mouth, or by injection into a vein or muscle.[2] Effects generally begin within an hour and last for about six hours.[2]
Common side effects include dizziness, low blood pressure, low blood potassium, muscle cramps, and kidney problems.[2] Other serious side effects may include hearing loss and low blood platelets.[2] Blood tests are recommended regularly for those on treatment.[2] Safety during pregnancy and breastfeeding is unclear.[3] Bumetanide is a loop diuretic and works by decreasing the reabsorption of sodium by the kidneys.[4][2]
Bumetanide was patented in 1968 and came into medical use in 1972.[5] It is on the World Health Organization's List of Essential Medicines.[6] It is available as a generic medication.[4] In 2020, it was the 270th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]